• Ting-Ting Ge, Xiao-Juan Pan, Xi-Meng Zuo, Xiao-Guang Shi, Yu-Kun Wang, Ping Sun, Xiang Gao, Xue Feng, Shuang Gao, and Tang-Shun Wang.
• Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
• Medicine (Baltimore). 2023 Dec 1; 102 (48): e36297e36297.

BackgroundBreast cancer is one of the most common type of cancers worldwide and remains a critical health issue. Although there are numerous treatment options for advanced metastatic breast cancer, the results are not satisfactory, particularly for triple-negative breast cancer. New treatment modalities need to be explored.Case PresentationWe present the case of a breast cancer patient with multiple metastases who achieved a good response and tolerance to the combination treatment of utidelone plus capecitabine. After being treated with 10 cycles of combined treatment, the patient is now in a good general condition with a progression-free survival time of 10 months.ConclusionTo our knowledge, this is the first report of utidelone plus capecitabine successfully treating a patient with heavily pretreated metastatic breast cancer. This combined treatment offers a new option for patients with multi-drug resistant breast cancer.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

21 keywords...

hide…